- Home
- RVPH vs CVKD Comparison
RVPH vs CVKD Comparison
Compare RVPH & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- CVKD
- Stock Information
- Founded
- RVPH 2006
- CVKD 2022
- Country
- RVPH United States
- CVKD United States
- Employees
- RVPH N/A
- CVKD N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- RVPH Health Care
- CVKD Health Care
- Exchange
- RVPH Nasdaq
- CVKD Nasdaq
- Market Cap
- RVPH 32.8M
- CVKD 29.5M
- IPO Year
- RVPH N/A
- CVKD 2023
- Fundamental
- Price
- RVPH $0.40
- CVKD $11.92
- Analyst Decision
- RVPH Strong Buy
- CVKD Strong Buy
- Analyst Count
- RVPH 5
- CVKD 1
- Target Price
- RVPH $9.00
- CVKD $32.00
- AVG Volume (30 Days)
- RVPH 3.8M
- CVKD 35.5K
- Earning Date
- RVPH 08-13-2025
- CVKD 08-06-2025
- Dividend Yield
- RVPH N/A
- CVKD N/A
- EPS Growth
- RVPH N/A
- CVKD N/A
- EPS
- RVPH N/A
- CVKD N/A
- Revenue
- RVPH N/A
- CVKD N/A
- Revenue This Year
- RVPH N/A
- CVKD N/A
- Revenue Next Year
- RVPH N/A
- CVKD N/A
- P/E Ratio
- RVPH N/A
- CVKD N/A
- Revenue Growth
- RVPH N/A
- CVKD N/A
- 52 Week Low
- RVPH $0.30
- CVKD $5.70
- 52 Week High
- RVPH $4.28
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- RVPH 36.63
- CVKD 36.41
- Support Level
- RVPH $0.38
- CVKD $11.15
- Resistance Level
- RVPH $0.45
- CVKD $13.63
- Average True Range (ATR)
- RVPH 0.04
- CVKD 0.99
- MACD
- RVPH 0.01
- CVKD 0.01
- Stochastic Oscillator
- RVPH 58.54
- CVKD 29.49
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.